Eblasakimab, an Anti-IL‑13Rα1 Antibody, Reduces Atopy-Associated Serum Biomarkers in Moderate‑to‑Severe Atopic Dermatitis
BioDrugs · 2024-11 · 38 (6) · 821-830
DOI: 10.1007/s40259-024-00685-y ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift BioDrugs, online erschienen am 15.10.2024. Verfasst von Ferda Cevikbas und 2 weiteren Autor:innen. Beteiligte Einrichtung: ASLAN Pharmaceuticals, 400 Concar Avenue, San Mateo, CA, 94402, USA. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Biomarkers, Chemokine CCL17, Immunoglobulin E. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: ASLAN Pharmaceuticals Pte Ltd.
Abstract (Originalsprache)
INTRODUCTION: Eblasakimab, a first-in-class monoclonal antibody with a unique mechanism to target the interleukin (IL)-13 receptor alpha 1 (IL-13Rα1), inhibits IL-4/IL-13 signaling in the pathophysiology of atopic dermatitis (AD). This study investigates the impact of eblasakimab on type 2 inflammatory biomarkers in patients with moderate-to-severe AD. METHODS: A double‑blind, multiple ascending dose, phase Ib study evaluated the effect of eblasakimab (200, 400, 600 mg) or placebo administered subcutaneously once weekly for 8 weeks in patients with moderate‑to‑severe AD. Serum levels of thymus and activation-regulated chemokine (TARC), total immunoglobulin E (IgE), and lactate dehydrogenase (LDH) were assessed. RESULTS: Eblasakimab suppressed TARC, IgE, and LDH in the 400-mg and 600-mg groups over 8 weeks of treatment. Patients in the 400-mg and 600-mg groups experienced a reduction of 72.8% (p = 0.004) and 62.9% (p = 0.003), respectively, for TARC, 35.1% (p = 0.006) and 20.9% (not significant; NS), respectively, for IgE, and 24.6% (NS) and 23.1% (NS), respectively, for LDH between baseline and Week 8. Reduction in serum TARC in the 400-mg group was significantly greater than placebo as early as Week 1, whereas reductions in total IgE were more gradual. Serum TARC and total IgE remained suppressed in the 400-mg and 600-mg eblasakimab groups for 4-6 weeks following the last administered dose. CONCLUSION: The effect of eblasakimab on circulating AD‑associated biomarker levels was accompanied by improvements in signs and symptoms of AD, consistent with the inhibition of IL-13 and IL-4 signaling via the type 2 receptor. TRIAL REGISTRATION NUMBER: NCT04090229.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- ASLAN Pharmaceuticals, 400 Concar Avenue, San Mateo, CA, 94402, USA.
- ASLAN Pharmaceuticals, 3 Temasek Avenue, Level 18, Singapore, Singapore.
- ASLAN Pharmaceuticals, 400 Concar Avenue, San Mateo, CA, 94402, USA. veverka.karen@yahoo.com.
- ASLAN Pharmaceuticals, 3 Temasek Avenue, Level 18, Singapore, Singapore. veverka.karen@yahoo.com.
Förderung
- ASLAN Pharmaceuticals Pte Ltd
Zitieren
APA
Cevikbas, F., Ward, A., & Veverka, K. A. (2024). Eblasakimab, an Anti-IL‑13Rα1 Antibody, Reduces Atopy-Associated Serum Biomarkers in Moderate‑to‑Severe Atopic Dermatitis. BioDrugs, 38(6), 821-830. https://doi.org/10.1007/s40259-024-00685-y
Vancouver
Cevikbas F, Ward A, Veverka KA. Eblasakimab, an Anti-IL‑13Rα1 Antibody, Reduces Atopy-Associated Serum Biomarkers in Moderate‑to‑Severe Atopic Dermatitis. BioDrugs. 2024;38(6):821-830. doi:10.1007/s40259-024-00685-y
BibTeX
@article{Cevikbas2024,
author = {Cevikbas, Ferda and Ward, Alison and Veverka, Karen A},
title = {Eblasakimab, an Anti-IL‑13Rα1 Antibody, Reduces Atopy-Associated Serum Biomarkers in Moderate‑to‑Severe Atopic Dermatitis},
journal = {BioDrugs},
year = {2024},
volume = {38},
number = {6},
pages = {821--830},
doi = {10.1007/s40259-024-00685-y}
}
EUVIMED